Sarepta Therapeutics stock was sliding again on Monday, as investors struggled to make sense of further bad news concerning ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

CAMBRIDGE, MA-- - Sarepta Therapeutics, Inc. , a developer of innovative RNA-based therapeutics, entered into an At-the-Market equity offering sales agreement with Citadel Securities LLC on ...